Ellagic acid nanoliposomes potentiate therapeutic effects of PEGylated liposomal doxorubicin in melanoma: An in vitro and in vivo study

• Published in: Journal of drug delivery science and technology Vol. 93; p. 105396
• Main Authors: Heidarian, Fatemeh, Alavizadeh, Seyedeh Hoda, Kalantari, Mahmoud Reza, Hoseini, Seyed Javad, Farshchi, Helaleh Kaboli, Jaafari, Mahmoud Reza, Doagooyan, Maham, Bemidinezhad, Abolfazl, Kesharwani, Prashant, Sahebkar, Amirhossein, Gheybi, Fatemeh
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.03.2024
• Subjects: Cancer; Combination therapy; Doxorubicin; Ellagic acid; Liposome; Synergistic; Synergistic; Liposome; Combination therapy; Doxorubicin; Ellagic acid; Cancer
• ISSN: 1773-2247
• DOI: 10.1016/j.jddst.2024.105396

Combination therapy is a promising strategy to enhance the efficacy of cancer treatment. Polyphenolic compounds including Ellagic acid (EA) have shown significant efficacy against several types of cancers. Despite considerable anti-tumor activity, the low aqueous solubility of EA hinders its application in cancer therapy. In the current study, we report on the preparation and characterization of EA liposome (EA Lip) and its combination with doxorubicin liposomes (Doxil) against B16F0 melanoma tumor in vitro, and in vivo in C57/BL6 mice model. In vitro study showed synergistic effects of EA Lip/Doxil combination at both 7:1 and 30:1 M ratios following 48 and 72 h incubation with B16F0 cells. For in vivo therapeutic efficacy, mice received a single intravenous injection of Doxil (5 mg/kg), EA Lip (3 mg/kg) and EA Lip/Doxil combination at 3 and 5 mg/kg, respectively, through the tail vein. In vivo results indicated a significant tumor shrinkage in mice received EA Lip in combination with Doxil compared to EA Lip or Doxil alone. Based on the survival data, combination therapy prolonged the survival of animals and the tumor growth delay percentage was reported to be 37.3% for the combination versus 24 and 14.6% for Doxil and EA Lip, respectively. These results laid emphasis on the benefits of combination strategy to improve the therapeutic outcome. Further studies however are warranted to elucidate the mechanism involved in the synergistic anti-proliferative effects of EA in combination with Doxil. [Display omitted]